EN
中文 EN
Innovation for a safer world
CanSinoBIO is an industry-leading biopharmaceutical company, dedicated to providing global solutions for the prevention and treatment of infectious diseases, through research & development, manufacturing and commercialization of vaccine products for human use.
More
5
Launched products
5
Technology platforms
10+
Diseases preventing
Innovation
Customer First
Global Vision
Advanced Technology
Prospects
News
062025
Company News
CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia®
More
062025
Company News
CanSinoBIO Launches First-in-Class Three-Component LNP Delivery System: Enhances T Cell Response and Safety, Surpassing Industry Patent Barriers
More
052025
Company News
CanSinoBIO Obtained Approval for Clinical Trials of Inhaled TB Vaccine in Indonesia
More
032025
Media Report
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
More
032025
Company News
SPIMACO and CanSinoBIO Sign an Agreement to Localise and Market the MCV4 Vaccine in Saudi Arabia and MENA
More
Social Responsibility
As a leading company in innovative vaccine research and development, we are unwavering in our commitment to providing solutions for the prevention and treatment of infectious diseases. We fulfill our social responsibilities by consistently providing high-quality vaccines and contributing to global public health.
More
Marketed Products
Menhycia®
More
Menphecia®
 More
Convidecia®
 More
Convidecia Air®
 More